Practical Aspects of Prescribing a Biologic

@article{Poulin2009PracticalAO,
  title={Practical Aspects of Prescribing a Biologic},
  author={Yves Poulin and Marc Bourcier},
  journal={Journal of Cutaneous Medicine and Surgery},
  year={2009},
  volume={13},
  pages={S101 - S93}
}
As the use of biologic agents for treatment of psoriasis becomes more common, practitioners need to be aware of the unique concerns and procedures required when prescribing biologics. This article describes the clinical and laboratory assessments that should occur before starting a biologic treatment, as well as the contraindications to consider for patients who might be candidates for biologic treatment. Important-treatment monitoring issues for safe and effective use of biologics in patients… 
View on SAGE
asocolderma.org.co
2 Citations
Background Citations
1

Figures, Tables, and Topics from this paper

2 Citations

Citation Type

Citation Type

Biologic Therapy in Psoriasis: Perspectives on Associated Risks and Patient Management
TLDR
Much of the evidence regarding the long-term safety of these agents has been based on experience in other patient populations, however, it does serve to guide us in understanding the risks that may impact the management of psoriasis patients.
A Refresher on Herpes Zoster, Current Status on Vaccination, and the Role of the Dermatologist
TLDR
Dermatologists should embrace zoster vaccination and recommend routine vaccination of immunocompetent individuals > age 60 years, as well as patients of any age who are starting immunosuppressants, including biologics.

References

SHOWING 1-10 OF 17 REFERENCES
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.
Tuberculosis in the age of biologic therapy.
Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel
BackgroundApproximately 2% of people worldwide have psoriasis, with as many as 1 million people with psoriasis in Canada alone.1,2 The severity of psoriasis ranges from mild to severe. It can lead to…
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
OBJECTIVE To determine the potential for additive or synergistic effects of combination therapy with the selective anti-tumor necrosis factor alpha agent etanercept and the anti-interleukin-1 agent…
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
OBJECTIVE To determine the potential for additive or synergistic effects of combination therapy with the selective anti-tumor necrosis factor alpha agent etanercept and the anti-interleukin-1 agent…
Clinical Pharmacokinetics and Use of Infliximab
Tumor necrosis factor-α (TNFα) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Infliximab, a chimeric (human-murine) monoclonal IgG1 anti-TNFα antibody, is used in the…
Problems encountered during anti-tumour necrosis factor therapy.
  • S. Desai, D. Furst
  • Medicine, Biology
    Best practice & research. Clinical rheumatology
  • 2006
...
1
2
...